A Johnson & Johnson unit working to resolve massive cancer litigation in bankruptcy court was accused by a former head of the ...

Elon Musk is vowing yet again to fire any federal workers who don’t respond to an email asking them to list five things they ...

Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the ...

FDA reform needs to be underpinned by strategy, not ‘indiscriminate’ cuts The Trump administration could save the lives of ...

As we observe Rare Disease Day today, let us take a look at seven drugs poised to be approved to address rare diseases in ...

Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...

Mr Johnson is an American entrepreneur and venture capitalist, best known for his anti-aging attempt that he refers to as ...

Zevra has sold its US Food and Drug Administration (FDA) priority review voucher (PRV) for $150m to an undisclosed party.

The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.

For Zevra Therapeutics, last year’s approval of the rare lysosomal storage disorder drug Miplyffa appears to be the gift that ...

As Robert F. Kennedy Jr. takes the helm of the Department of Health and Human Services, his policies on chronic disease, ...